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Background: Reduction of retinal nerve fibre layer (RNFL) thickness was shown as part of the neurodegenerative
process in a range of different neurodegenerative pathologies including Alzheimer0s disease (AD), idiopathic
Parkinson’s disease (PD), spinocerebellar ataxia (SCA) and multiple system atrophy (MSA). To further clarify the
specificity of RNFL thinning as a potential marker of neurodegenerative diseases we investigated RNFL thickness in
Hereditary Spastic Paraplegia (HSP), an axonal, length-dependent neurodegenerative pathology of the upper motor
neurons.
Methods: Spectral domain optical coherence tomography (OCT) was performed in 28 HSP patients (clinically: pure
HSP = 22, complicated HSP = 6; genetic subtypes: SPG4 = 13, SPG5 = 1, SPG7 = 3, genetically unclassified: 11) to
quantify peripapillary RNFL thickness. Standardized examination assessed duration of disease, dependency on
assistive walking aids and severity of symptoms quantified with Spastic Paraplegia Rating Scale (SPRS).
Results: HSP patients demonstrated no significant thinning of global RNFL (pglobal = 0.61). Subgroup analysis
revealed significant reduction in temporal and temporal inferior sectors for patients with complex (p<0.05) but not
pure HSP phenotypes. Two of three SPG7-patients showed severe temporal and temporal inferior RNFL loss.
Disease duration, age and severity of symptoms were not significantly correlated with global RNFL thickness.
Conclusion: Clinically pure HSP patients feature no significant reduction in RNFL, whereas complex phenotypes
display an abnormal thinning of temporal and temporal inferior RNFL. Our data indicate that RNFL thinning does
not occur unspecifically in all neurodegenerative diseases but is in HSP restricted to subtypes with multisystemic
degeneration.
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Optical coherence tomography (OCT)Background
Hereditary spastic paraplegias (HSPs) are a group of
genetically determined progressive neurodegenerative
disorders where dysfunction of axonal transport pro-
cesses predominantly leads to a length-dependent de-
generation of corticospinal tract fibres [1]. They are
clinically classified as “pure” or “uncomplicated” HSPs
when the pathology is limited to the core symptom of
progressive lower limb weaknesses and spasticity, op-
tionally accompanied by neurogenic bladder disturbance* Correspondence: sarah.wiethoff@uni-tuebingen.de; ludger.schoels@uni-
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reproduction in any medium, provided the orand mild diminution of lower-extremity vibration sense.
“Complicated” or “complex” HSPs additionally show dif-
ferent system involvement including cerebellar affection,
lower motor neuron involvement, sensory impairment,
peripheral neuropathy, dementia, mental retardation and
more rarely deafness, psychiatric disorders, seizures,
extrapyramidal signs or extraneurological signs (e.g. ich-
thyosis) [2-4]. Ophthalmologic affection like congeni-
tal cataract, optic atrophy or retinitis pigmentosa has
not been systematically studied but is only rarely
reported [5].
HSPs are genetically heterogenous and can be inher-
ited as autosomal dominant, autosomal recessive, or
X-linked recessive trait. So far at least 48 chromosomal
loci are associated with HSP referred to as spasticl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mon subtype is SPG4 with an autosomal-dominant in-
heritance and a predominantly pure phenotype [7].
The retinal ganglion cells deliver a unique study object
with their unmyelinated axons and direct synapses into
the central nervous system. Optical coherence tomog-
raphy is a highly suitable method to study the thickness
of retinal nerve fibre layer in vivo and non-invasively.
There is clear evidence for RNFL thinning in multiple
sclerosis (MS) with and without optic neuritis as well as
in neurodegenerative pathologies like Multiple System
Atrophy (MSA), Alzheimer disease (AD), Parkinson’s
disease (PD) or degenerative ataxias [8-13]. Yet, to our
knowledge by submission, no study has been performed
to investigate RNFL in HSP patients which makes the
study an important addendum in order to gain more
insight into the pathology of HSP and address the ques-
tion, whether RNFL thinning represents a rather non-
specific affection in all neurodegenerative disorders, or
whether it might retain some specificity. HSP is a perfect
model to address this question as it is thought to derive
from distal axonopathy e.g. due to axonal transport
defects. HSP preferentially affects the longest axons of
the corticospinal tracts declining to the legs and spares
shorter axons like those innervating the arms. Retinal
axons comprising the RNFL are comparably short and
thus would be expected to remain spared in case RNFL
reduction is not an unspecific marker of neurodegenera-
tive per se. To investigate possible RNFL reduction in
HSP patients, we designed a prospective observational
study as our observations e.g. in MSA patients with sig-
nificant RNFL thinning confirm, that these changes
might very well remain subclinical and not likely to be




We prospectively examined 31 HSP patients, 7 of com-
plex and 24 of pure phenotype (HSP-c and HSP-p, re-
spectively). Diagnosis of HSP was made according to
Harding and GeNeMove criteria [2,14]. Inclusion criteria
included (distant) best corrected visual acuity (D-BCVA)
of < 0.3 logarithm of the minimum angle of resolution
(logMAR), spherical ametropia of ≤ ± 4 dpt. and cylin-
drical ametropia ≤ ± 2 dpt. Exclusion criteria comprised
the existence of other neurodegenerative diseases or
ocular pathology that could falsify test results, e.g. glau-
comatous neuropathies which led to a final study popu-
lation of 28 patients.
Disease causing mutations were known for 17 of 28
patients including 13 patients with SPAST mutation
(SPG4; all with clinically pure phenotypes), 3 with para-
plegin mutations (SPG7; two clinically complex, onepure), 1 with CYP7B1 mutations (SPG5 with pure pheno-
type). The control group consisted of 28 healthy subjects
matched for gender with mean age of 38 years (SD: 10,3)
who met the same ophtalmological inclusion and exclu-
sion criteria and did not show any sign of spastic parapar-
esis or other neurological disorder.
The independent ethics committee of the University of
Tuebingen approved the study, which was performed in
accordance to the ethical standards of the Declaration of
Helsinki (1964). All patients gave written informed con-
sent prior to their inclusion in the study.
Retinal Imaging
An initial complete ophthalmologic exam was performed
to exclude confounding neuroophthalmological disor-
ders such as glaucoma. Spectral domain optical coher-
ence tomography (SD-OCT) imaging and analysis was
performed using the Spectralis HRA + OCT platform
(Heidelberg Engineering, Heidelberg, Germany) with
real time compensation for eye movements as described
elsewhere [9]. Briefly, for quantification of central retinal
thickness (CRT) and RNFL thickness, we used the pro-
prietary Eye Explorer software (version 5.1), which auto-
matically defines RNFL thickness as distance between
inner limiting membrane (ILM) and ganglion cell layer
(GCL) and CRT as distance between ILM and retinal
pigment epithelium. For acquisition of circular scans, a
mean of 16 images was calculated with automated align-
ment of iterative recordings using the automated real-
time mode, thereby increasing the signal-to-noise ratio
by a factor of four [15]. CRT was measured from trans-
verse sections (also using averaged recordings of 16
images) through the foveal center in an orthogonal fash-
ion (cross hair) to exclude oblique measurements due to
tilt. Scans with poor quality (< 20 dB) were excluded
from the analysis.
Neurological examination
Age of onset was defined as the onset of a progressive
gait disorder. Family history covered first and second de-
gree relatives. Disease severity and complicating symp-
toms were assessed by the Spastic Paraplegia Rating
Scale (SPRS) [14]. SPRS-scores range from 0–52 points
with higher scores indicating more severe disease. Com-
plicating symptoms are reflected in a clinical inventory.
See Table 1 for mean age, disease duration, clinical fea-
tures and SPRS scoring for all HSP patients as well as
subgroups.
Statistical analysis
All data are reported as mean value +/−standard deviation
(SD) and a p-value of < 0.05 was regarded as statistically
significant (data uncorrected for multiple comparisons).
To assess whether a correlation exists between OCT-data
Table 1 Clinical data of the whole cohort as well as clinical and molecular-genetic subtypes
Age [years] Disease duration [years] SPRS [scoring points] Phenotype
HSP-a (n=28) 48.1 (8–75) 19.1 (4–40) 20.8 (3–30) complex & pure, see subgroups
HSP-p (n=22) 49.5 (8–75) 21.8 (5–43) 21.5 (3–31) spastic paraparesis, pure phenotype
HSP-c (n=6) 42.8 (22–60) 9.5 (4–18) 18 (8–31) most frequent complicating symptoms:
gaze-evoked-nystagmus or ataxia
SPG4 (n=13) 46.1 (8–74) 21.5 (7–37) 20.8 (3–30) spastic paraparesis, pure phenotype
SPG5 (n=1) 48 43 23 pure phenotype
SPG7 (n=3) 38.3 (28–48) 9.7 (4–14) 17.7 (8–31) one pure, two complex phenotypes (see text)
Data are given as mean values and range in brackets for all HSP-patients (HSP-a) and for clinically pure phenotypes (HSP-p), complex phenotypes (HSP-c) as well
as molecular-genetic (SPG4, SPG5, SPG7) subgroups.
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correlation test was used.
Analysis of variance (ANOVA) was used to determine
a significant difference in foveal thickness and RNFL
thickness sector data sets (JMP V8.02, SAS Institute
Inc., Cary, USA).
Results
Ophthalmologic examination showed signs of confound-
ing ocular pathology in none of the healthy controls but
in three of the patients. Two pure HSP patients with a
mutation of the SPG4 gene and one patient with com-
plex HSP displayed glaucomatous optic disc cupping
with positive family history of primary open angle glau-
coma in 2 of 3 patients. These patients were excluded
from further analysis via OCT. One patient with SPG7
was diagnosed with optic atrophy but was not excluded
from the analysis as optic atrophy was regarded as part
of the multidegenerative process in complex HSP that is
subject of this study.
Spectral domain optical coherence tomography (SD-OCT)
Quality indices (signal to noise ratio [dB]) of OCT
recordings in both groups were high (HSP: 29.96 ± 4.63,
range 21.00 - 42.00; CTRL: 29.43 ± 3.05, range 24.00 -
38.00) indicating robust primary data sets.
Whole HSP-cohort
HSP patients demonstrated a tendency to reduced foveal
thickness and thinning of overall RNFL, which both
failed to reach statistical significance compared to the
control group. Changes in RNFL did not describe a uni-
form pattern in HSP. Rather, temporal superior and
nasal superior sectors showed tendencially increased
RNFL thickness in patients compared to healthy con-
trols, whereas a slight reduction in RNFL thickness in
patients was observed in temporal, nasal, nasal inferior,
and temporal inferior sectors. Overall, greatest change
was observed in foveal total retinal thickness measure-
ments of HSP patients.Pure HSP
Patients with pure HSP did neither show any significant
reduction of global RNFL nor thinning in any of the in-
dividual sectors. Only total retinal thickness at the fovea
was significantly thinner in patients with pure HSP
(p<0.05).
Complex HSP
In patients with complex forms of HSP (HSP-c) RNFL
thickness was significantly reduced within temporal
(p<0.05) and temporal inferior sections (p<0.05).
SPG4
All SPG4-patients displayed a clinically pure phenotype.
No abnormalities of RNFL were observed apart from
reduced foveal total retinal thickness (p<0.05).
SPG5
The SPG5-patient presented with a pure clinical pheno-
type and RNFL measurements within the normal range
in all retinal sectors.
SPG7
Two of three SPG7 patients had complex phenotypes.
One 39 year old with a disease duration of 4 years pre-
sented with ataxia and gaze-evoked nystagmus as com-
plicating symptoms. The second patient was diagnosed
with optic atrophy and displayed cognitive impairment,
dysarthria and gaze-evoked nystagmus in addition to
spastic paraplegia. The third SPG7-patient had pure
spasticity of lower limbs with a disease duration of 11
years without complicating symptoms.
The two patients with complex phenotypes showed a
global RNFL thickness outside normal limits, especially
the temporal RNFL was decreased in both patients. Add-
itionally, the nasal superior sector was borderline to
pathology in one SPG7 patient and the nasal inferior
sector in the other complex SPG7 patient. Nasal and
temporal superior quadrants did not depict reduction of
RNFL thickness (Figure 1). In the third SPG7-patient
with a clinically pure phenotype no abnormalities in
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in Table 2.Correlation with clinical features
Visual acuity
Our data set of visual acuity in complex and pure HSP
patients was collected using standard ETDRS visual acu-
ity tests and subgroup analysis showed no significant dif-
ference in visual acuity (HSPcomplex: 0.02 ± 0.08, range
−0.10 - 0.10; HSPpure: -0.01 ± 0.07, range −0.10 - 0.10;
p = 0.47). There was no significant difference regarding
visual function in the HSP cohort compared to healthy
controls (HSP: 0.00 ± 0.07, range −0.10 - 0.10; CTRL:
-0.02 ± 0.07, range −0.10 - 0.10; p = 0.58). Furthermore,
there was no significant correlation between RNFL thick-
ness and visual function in these cohorts (rHSP = 0.19;
rCTRL = 0.01).Disease severity
There was no significant correlation between thickness of
global RNFL or RNFL in different retinal sectors and dis-
ease severity quantified by SPRS score (r2global RNFL versus
severity = 0.05), disease duration (r
2
global RNFL versus duration =
0.01) or age (r2global RNFL versus age = 0.03) in the whole
HSP-cohort. Within subgroups, correlation with clinical
data did not reveal significant results.Figure 1 Exemplary SD-OCT data sets in individual pure (top) and com
of the optic nerve head and indicate placement of the peripapillary ring sc
by simultaneous scanning laser ophthalmoscopy. In the patient with pure
retina demonstrates a normal RNFL thickness (delineated by the red lines).
displayed as black line in front of data from the normative data set provide
intervall, yellow area = 99% CI, red area = outside 99% CI). Conversely, reco
decreased RNFL thickness. This was most pronounced in the temporal secto
and nasal inferior (72 μm, norm: 109 μm) sectors were borderline to patholo
norm: 102 μm) and temporal superior (121 μm, norm: 141 μm) sectors did nDiscussion
Our study presents first data on RNFL measures in HSP
patients in order to target the question whether RNFL loss
can be observed unspecifically in any form of neurodegen-
erative disorder and whether the distribution pattern
within the retina is specific for single disease entities as
previously suggested [10,16]. Interestingly, some studies
investigating RNFL in different neurodegenerative diseases
claimed specific patterns of RNFL loss for the different
disease entities even though there are still controversial
findings to report on: E.g. in idiopathic Parkinson’s disease
(PD), one study showed the RNFL to be significantly
reduced in the (inferior-) temporal sector [10], other stud-
ies revealed statistically significant decrease of global
RNFL [17] or reduced inner retinal thickness (RNFL, gan-
glion cell and inner plexiform layer) in both inferior and
superior macular fields [16], while another study did not
detect any statistically significant difference in measure-
ments of retinal thickness at all [18]. According to the lim-
ited amount of published data available regarding RNFL
in degenerative ataxias, patients with spinocerebellar atax-
ias type SCA1, SCA2 and SCA3 showed decreased RNFL
thickness, whereas a reduced macular thickness was found
in patients with SCA 1, 3 and 6 but not SCA2 [13,19].
OCT-measurements in MSA patients showed significant
reduction of RNFL in nasal quadrants compared to
healthy controls [9]. In contrast, patients suffering fromplex (bottom) HSP patients. Left panels (a,d) demonstrate anatomy
an (green circle) in relation to the point of fixation (blue line) recorded
HSP (SPG4), the acquired virtual cross section (b) of the peripapillary
Quantitative spatial analysis (c) of this individuals RNFL thickness is
d by the software (green line = mean, green area = 95% confidence
rdings from a SPG7 patient with complex HSP (d-f) indicate severely
r (43 μm, norm: 81 μm). Both temporal inferior (113 μm, norm: 152 μm)
gic levels, whereas nasal (66 μm, norm: 72 μm), nasal superior (97 μm,
ot show significant reduction.



































































































Data shown in μm as mean ± SD. Statistic comparison of subgroups was performed to the corresponding number of healthy controls. P-value as revealed by
ANOVA if applicable (with restrictions to SPG7-subgroup (n=3) and SPG5-subgroup (n=1), p* = p < 0.05 (p uncorrected)). For abbreviations, see Table 1.
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the superior quadrant in one study [20] while all quad-
rants were reported affected in another study [12]. Final
evidence of specific reduction patterns for each underlying
neurodegenerative disorder has not yet been yielded, but
most available data seem to confirm the notion that neu-
rodegenerative/-inflammatory disorders such as AD, PD,
MSA, some SCAs and MS are associated with a significant
loss of retinal nerve fibres. While these observations have
been gathered using different generations of OCT devices
of varying axial resolution, signal to noise ratio and meth-
ods of artifact reduction, new studies from latest gener-
ation OCT devices further substantiate previous findings
of significant morphological differences on a retinal
level in patients with neurodegenerative/-inflammatory
disorders [21,22].
In this study, HSP patients, in contrast to patients with
other neurodegenerative disorders showed only a ten-
dency towards global thinning of RNFL, but no statisti-
cally significant changes. RNFL thickness (global as well as
within different sectors) did not correlate with clinical se-
verity, duration of disease or age. This is in line with the
current notion of molecular pathogenesis of HSP as
a length dependent axonal degeneration, which widely
restricts the degenerative process to neuronal fibre tracts
with the longest axons e.g. corticospinal tracts, dorsal
column and peripheral nerves of the lower limbs. Even
though molecular mechanisms responsible for the as-
sumed axonal degeneration in HSP are only partially
understood, our findings fit into this concept. Here we
show, that retinal ganglion cell axons forming the retinal
nerve fibre layer are not affected by the degenerative
process in pure HSP. This finding for the first time can
bring up scientific data that discards the assumption of
RNFL loss being an unspecific surrogate marker for all
forms of neurodegeneration.In contrast, patients with complex forms of HSP where
the disease spreads beyond the long fibre tracts presented
significant thinning of RNFL especially in temporal and
temporal inferior sectors. These changes reached signifi-
cance despite the small number of individuals with com-
plex HSP included in this study. However, these changes
were not statistically significant after correction for mul-
tiple comparisons and need to be reproduced in a larger
cohort of patients with complex HSP. This may also help
to depict genotype specific effects. So far we found
patients with mutations in the nuclear-encoded mitochon-
drial AAA metalloproteinase paraplegin causing SPG7
[23] to present with retinal changes. Interestingly, within
the small group of SPG7-patients abnormal thinning of
RNFL was restricted to the two patients with complex
phenotypes.
As mitochondrial defects are thought to play a crucial
role in the pathogenesis of SPG7 and affection of retinal
ganglion cells as well as optical atrophy are a common fea-
ture of other mitochondriopathies [5] it would be interest-
ing to see whether thinning of the RNFL is a common
feature in other mitochondriopathies. Our observation
suggests that underlying mitochondrial pathology and a
complex phenotype in HSP may predispose for developing
optical atrophy. Further stratification of this risk potential
is clearly needed in a bigger cohort of SPG7-patients but
personal communication (Alexandra Dürr) suggests that
RNFL is indeed frequently altered in SPG7. It would be of
interest to learn whether patients with SPG31, another
rare subform of HSP with mitochondrial dysfunction [24]
also present RNFL loss like SPG7.
Conclusions
As a conclusion, our study demonstrated that the RNFL
is affected in the majority of HSP patients with complex
phenotypes, but is not altered in SPG4 and pure forms
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RNFL loss is not an unspecific change in any neurode-
generative disease but might emerge in certain subforms
depending on the underlying molecular-genetic path-
ology and phenotype. One limiting factor concerning re-
liability of the data presented here definitively is the
heterogeneity of the investigated cohort and the compar-
ably small number of complex phenotypes studied.
Therefore larger cohort studies will be needed to con-
firm the findings.
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